How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

394 results for

Clinical Index of Stable Febrile Neutropenia

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Bipolar disorder

2011. February 2011 — topic structure revised to ensure consistency across CKS topics - no changes to clinical recommendations have been made. October 2010 — minor update. Information on fitness to drive from the Driver and Vehicle Licensing Agency's guidance for medical practitioners, At a glance guide to the current medical standards of fitness to drive has been added. Issued in October 2010. July 2010 — minor update. Prescribing information on Lithium updated to reflect new advice in the Summary (...) with bipolar disorder and ~50% of people with unipolar depression). Earlier age of onset (peak age 15 to 19 years), abrupt onset (possibly triggered by stressor). More frequent episodes of shorter duration. Comorbid substance misuse. Higher post-partum risk. Psychosis, psychomotor retardation, and catatonia. Lower likelihood of somatic symptoms. Note: a of bipolar disorder may also raise clinical suspicion. Note that the diagnostic criteria for bipolar disorder in children and young people state

2019 NICE Clinical Knowledge Summaries

102. Heart failure - chronic

or are readmitted within 1 year. If heart failure is suspected clinically they should have their serum natriuretic peptide level measured. If the level is normal, a diagnosis of heart failure is unlikely. If levels are raised, referral for specialist assessment and echocardiography should be arranged. Because very high levels of NT‑proBNP carry a poor prognosis, refer people with suspected heart failure and an NT‑proBNP level above 2,000 ng/litre (236 pmol/litre) urgently, to have specialist assessment (...) heart failure with reduced ejection fraction: To relieve symptoms of fluid overload, a diuretic should be prescribed. To reduce morbidity and mortality, an angiotensin-converting enzyme (ACE) inhibitor and a beta-blocker should be prescribed. One drug should be introduced at a time, adding the second drug once the person is stable on the first drug. If the person is still symptomatic despite optimal treatment with an ACE-inhibitor and beta-blocker, a referral for specialist management should

2019 NICE Clinical Knowledge Summaries

103. Neutropenic sepsis

, according to the National Institute for Health and Care Excellence (NICE) [ ]. The definition of neutropenia using absolute neutrophil count varies in the literature [ ; ; ; ]. The risk of clinically significant infection and sepsis increases as the neutrophil count decreases to less than 0.5 x 10 9 /L [ ; ]. Febrile neutropenia is the most common complication of anticancer treatment, and describes the presence of fever in a person with neutropenia [ ] . The exact definition of febrile neutropenia (...) ) [ ], the international consensus report Surviving Sepsis Campaign (SSC): International Guidelines for Management of Sepsis and Septic Shock: 2016 [ ], the UK Sepsis Trust Sepsis Manual [ ] , and expert opinion in a review article on sepsis [ ], on neutropenic sepsis [ ; ], and on febrile neutropenia [ ; ]. Maintaining a high index of suspicion of neutropenic sepsis The information that neutropenic sepsis can be challenging to identify due to minimal or atypical symptoms and/or signs is based on the ESMO clinical

2019 NICE Clinical Knowledge Summaries

104. Crizotinib (Xalkori) Resubmission for First Line Advanced NSCLC

Crizotinib (Xalkori) Resubmission for First Line Advanced NSCLC pan-Canadian Oncology Drug Review Initial Clinical Guidance Report Crizotinib (Xalkori) Resubmission for Advanced or Metastatic Non-Small Cell Lung Cancer July 3, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended to help Canadian health systems leaders and policymakers make well-informed decisions and thereby improve the quality of health care services. While patients and others may use (...) this report, they are made available for informational and educational purposes only. This report should not be used as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision making process, or as a substitute for professional medical advice. Liability pCODR does not assume any legal liability or responsibility for the accuracy, completeness or usefulness of any information, drugs, therapies, treatments, products

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

105. Pruning Emtree: Does Focusing Embase Subject Headings Impact Search Strategy Precision and Sensitivity?

that there are thousands of reports of RCTs indexed in Embase that are not also indexed in MEDLINE. 2 Although Embase is a recommended key database it has several features that hinder efficient searching. One feature is the large number of Emtree index terms that are added to most Embase records: an average of 3 to 4 major terms and up to 50 minor terms. 3 MEDLINE records may contain an average of 10 to 20 (major or minor) index terms. 4 The volume of index terms can lead to poor precision in Embase searches (large (...) proportions of irrelevant records are retrieved) if the terms that are of only marginal relevance to a specific record are added by the indexers. When this occurs it can add to the record processing burden within the HTA process. This experience has led to informal pragmatic recommendations that search results can be reduced by carrying out searches of subject headings combined with subheadings (qualifiers) and/or searches with subject headings limited to those with a major focus (major headings). 4

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

106. Melanoma Treatment (PDQ®): Health Professional Version

as the source cell for melanoma. The relatively avascular epidermis houses both basal cell keratinocytes and squamous epithelial keratinocytes, the source cells for basal cell carcinoma and squamous cell carcinoma, respectively. The separation between epidermis and dermis occurs at the basement membrane zone, located just inferior to the basal cell keratinocytes. Screening Refer to the PDQ summary on for more information. Clinical Features Melanoma occurs predominantly in adults, and more than 50 (...) of primary and metastatic tumors. The most important prognostic factors have been incorporated into the revised 2009 American Joint Committee on Cancer staging and include the following:[ , - ] Thickness and/or level of invasion of the melanoma. Mitotic index, defined as mitoses per millimeter. Ulceration or bleeding at the primary site. Number of regional lymph nodes involved, with distinction of macrometastasis and micrometastasis. Systemic metastasis. - Site—nonvisceral versus lung versus all other

2018 PDQ - NCI's Comprehensive Cancer Database

107. Adult Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version

areas. Presence of . Early favorable group: Clinical stage I or II without any of the adverse prognostic factors listed above. Early unfavorable group: Clinical stage I or II with one or more of the adverse prognostic factors listed above. Advanced-stage adverse prognostic factors: For patients with advanced-stage HL, the International Prognostic Factors Project on Advanced Hodgkin's Disease developed the International Prognostic Index with a score that is based on the following seven adverse (...) seen. Risk Factors Risk factors for adult HL include the following: Being in early adulthood (aged 20–39 years) (most often) or late adulthood (aged 65 years and older) (less often). Being male. Having a previous infection with the Epstein-Barr virus in the teenage years or early childhood. Having a first-degree relative with HL. Clinical Features These and other signs and symptoms may be caused by adult HL or by other conditions: Painless, swollen lymph nodes in the neck, axilla, or inguinal area

2018 PDQ - NCI's Comprehensive Cancer Database

108. Breast Cancer Treatment (PDQ®): Health Professional Version

).[ ] Aromatase inhibitors or inactivators.[ , ] Risk-reducing mastectomy.[ ] Risk-reducing oophorectomy or ovarian ablation.[ - ] (Refer to the PDQ summary on for more information about factors that decrease the risk of breast cancer.) Screening Clinical trials have established that screening asymptomatic women using mammography, with or without clinical breast examination, decreases breast cancer mortality. (Refer to the PDQ summary on for more information.) Diagnosis Patient evaluation When breast cancer (...) is suspected, patient management generally includes the following: Confirmation of the diagnosis. Evaluation of the stage of disease. Selection of therapy. The following tests and procedures are used to diagnose breast cancer: Mammography. Ultrasound. Breast magnetic resonance imaging (MRI), if clinically indicated. Biopsy. Contralateral disease Pathologically, breast cancer can be a multicentric and bilateral disease. Bilateral disease is somewhat more common in patients with infiltrating lobular

2018 PDQ - NCI's Comprehensive Cancer Database

109. Gastric Cancer Treatment (PDQ®): Health Professional Version

with patients who received CF (9.2 months; 95% CI, 8.4–10.6; vs. 8.6 months; 95% CI, 7.2–9.5; HR, 1.29; 95% CI, 1.0–1.6; log-rank P = .02; risk reduction = 23%).[ ][ ] There were high toxicity rates in both arms.[ ] Febrile neutropenia was more common in patients who received DCF (29% vs. 12%), and the death rate on the study was 10.4% for patients on the DCF arm and 9.4% for patients on the CF arm. Whether the CF regimen should be considered as an index regimen for the treatment of patients with metastatic (...) = .0162). Toxicity rates were similar between groups (26% required hospitalizations in the ECF/ECX group and 25% in the FLOT group). However, types of side effects differed, with increased nausea, thromboembolic events, and anemia in the ECF/ECX group versus higher rates of grade 3/4 infections, neutropenia, diarrhea, and neuropathy in the FLOT group. Treatment Options Under Clinical Evaluation for Stage I Gastric Cancer Treatment options under clinical evaluation for stage I gastric cancer include

2018 PDQ - NCI's Comprehensive Cancer Database

110. Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®): Health Professional Version

carcinomas share molecular findings, such as loss or inactivation of the tumor-suppressor p53 and BRCA1 or BRCA2 proteins.[ ] Therefore, high-grade serous adenocarcinomas arising from the fallopian tube and elsewhere in the peritoneal cavity, together with most ovarian epithelial cancers, represent extrauterine adenocarcinomas of Müllerian epithelial origin and are staged and treated similarly to ovarian cancer. Since 2000, FTC and PPC have usually been included in ovarian cancer clinical trials (...) for ovarian (epithelial) cancer include the following: Family history of ovarian cancer.[ - ] - A first-degree relative (e.g., mother, daughter, or sister) with the disease. Inherited risk.[ ] - BRCA1 or BRCA2 gene mutations.[ , ] Other hereditary conditions such as hereditary nonpolyposis colorectal cancer (HNPCC; also called Lynch syndrome).[ , ] Endometriosis.[ - ] Hormone therapy.[ , ] - Postmenopausal hormone replacement therapy. Obesity.[ - ] - High body mass index. Tall Height. [ - ] Family history

2018 PDQ - NCI's Comprehensive Cancer Database

111. Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version

on the for specific information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors.) On the basis of immunophenotype, molecular biology, and clinical response to treatment, the vast majority of NHL cases occurring in childhood and adolescence fall into three categories: (Burkitt and Burkitt-like lymphoma/leukemia, diffuse large B-cell lymphoma, and primary mediastinal B-cell lymphoma). . . Other rare types of pediatric NHL include the following (...) years, although outcome depends on a number of factors, including clinical stage and histology.[ ] Prognostic factors for childhood NHL include the following: . . . . . Response to therapy Response to therapy in pediatric lymphoma is one of the most important prognostic markers. Regardless of histology, pediatric NHL that is refractory to first-line therapy has a very poor prognosis.[ - ] Burkitt lymphoma/leukemia: One of the most important predictive factors is response to the initial prophase

2018 PDQ - NCI's Comprehensive Cancer Database

112. Recommendations for the use of first-line chemotherapy for the treatment of women with epithelial ovarian cancer

Oncology. 2011; 120S98 69. Pavelka JC, Brown RS, Karlan BY, et al. Effect of obesity on survival in epithelial ovarian cancer. Cancer. 2006; 107(7):1520-4 70. Au-Yeung G, Webb PM, DeFazio A, et al. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecol Oncol. 2014; 133(1):16-22 71. Laskey RA, Poniewierski MS, Lopez MA, et al. Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian (...) Recommendations for the use of first-line chemotherapy for the treatment of women with epithelial ovarian cancer First-line chemotherapy for the treatment of women with epithelial ovarian cancer Recommendations for the use of first-line chemotherapy for the treatment of women with epithelial ovarian cancer June 2014 | Incorporates published evidence to March 2014 A CLINICAL PRACTICE GUIDELINE DEVELOPED BY CANCER AUSTRALIA This document supplements information about use of chemotherapy for women

2015 Cancer Australia

113. Multiple Myeloma: Evidence Report

Multiple Myeloma: Evidence Report ©Institute for Clinical and Economic Review, 2016 Treatment Options for Relapsed or Refractory Multiple Myeloma: Effectiveness, Value, and Value-Based Price Benchmarks Evidence Report May 5, 2016 Institute for Clinical and Economic Review ©Institute for Clinical and Economic Review, 2016 Page ii Evidence Report – Multiple Myeloma Return to Table of Contents AUTHORS ICER Staff University of Washington School of Pharmacy Modeling Group Daniel A. Ollendorf, PhD (...) Chief Scientific Officer, Institute for Clinical and Economic Review Rick Chapman, PhD, MS Director of Health Economics, Institute for Clinical and Economic Review Sonya Khan, MPH Program Director, Institute for Clinical and Economic Review Elizabeth T. Russo, MD Research Scientist, Institute for Clinical and Economic Review Patricia G. Synnott, MALD, MS Research Associate, Institute for Clinical and Economic Review Steven D. Pearson, MD, MSc President, Institute for Clinical and Economic Review

2016 California Technology Assessment Forum

114. Term small for gestational age baby

) • Avoid hyperthermia by not over dressing the baby, monitoring equipment (e.g. incubator) and the baby’s temperature 16 • Document baby and equipment temperature, as well as interventions Queensland Clinical Guideline: Term small for gestational age baby Refer to online version, destroy printed copies after use Page 12 of 21 3.5 Hypoglycaemia, feeding and polycythaemia Table 9. Hypoglycaemia, feeding and polycythaemia Aspect Consideration Hypoglycaemia • SGA babies are at increased risk (...) Term small for gestational age baby Maternity and Neonatal C linical G uideline Queensland Health Term small for gestational age baby Queensland Clinical Guideline: Term small for gestational age baby Refer to online version, destroy printed copies after use Page 2 of 21 Document title: Term small for gestation age baby Publication date: July 2016 Document number: MN16.16-V4-R21 Document supplement: The document supplement is integral to and should be read in conjunction with this guideline

2016 Queensland Health

115. Initial Diagnostic Workup of Acute Leukemia

Context.—A complete diagnosis of acute leukemia requires knowledge of clinical information combined with morphologic evaluation, immunophenotyping and karyo- type analysis, and often, molecular genetic testing. Although many aspects of the workup for acute leukemia are well accepted, few guidelines have addressed the different aspects of the diagnostic evaluation of samples from patients suspected to have acute leukemia. Objective.—To develop a guideline for treating physi- cians and pathologists (...) with the incorporation of advanced laboratory techniques. The ?rst broadly accepted classi?cation in modern history was that of the French-American-British (FAB) cooperative group, which was initially based entirely onmorphologicfeaturesofblastcellsonWright-orWright- Giemsa–stained bone marrow smears and a variety of cytochemical stains. 1 With the introduction of clinical immunophenotyping assays, particularly ?ow cytometry immunophenotyping (FCI), the FAB classi?cation was modi?ed to incorporate limited

2016 College of American Pathologists

116. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association Circulation. 2016;134:e579–e646. DOI: 10.1161/CIR.0000000000000455 December 6, 2016 e579 CLINICAL STATEMENTS AND GUIDELINES T he intent of this American Heart Association (AHA) scientific statement is to summarize our current understanding of dilated cardiomyopathies. There is special emphasis on recent developments in diagnostic approaches and therapies (...) for specific cardiomyopathies. Recommendations in this document are based on published studies, published practice guidelines from the American College of Cardiology (ACC)/AHA 1 and other organizations, 2,3 and the multidis- ciplinary expertise of the writing group. Existing evidence in epidemiology, clas- sification, diagnosis, and management of specific cardiomyopathies is usually derived from nonrandomized observational studies, registries, case reports, or expert opinion based on clinical experience

2016 American Heart Association

117. U.S. Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of nontuberculous mycobacteria in individuals with cystic fibrosis Full Text available with Trip Pro

that might contribute to NTM acquisition in individuals with CF include: low vitamin D, , the presence of gastro-oesophageal reflux disease, , low body mass index , or malnutrition. Screening How often should individuals with CF be screened for NTM? Recommendation 2 : The CF Foundation and the ECFS recommend that cultures for NTM be performed annually in spontaneously expectorating individuals with a stable clinical course. Recommendation 3 : The CF Foundation and the ECFS recommend that, in the absence (...) ’ (NTM-PD), , which is defined by the presence of specific microbiological, clinical and radiological features described in Diagnosis of NTM-PD in CF section. However, it has become clear that NTM can also transiently, intermittently or permanently reside within the lungs of individuals with CF without causing NTM-PD, thus representing asymptomatic infection and creating considerable difficulties in deciding how best to screen for and diagnose NTM. Further challenges exist in knowing how best

2016 Cystic Fibrosis Foundation

118. Practice Guidelines for the Diagnosis and Management of Aspergillosis Full Text available with Trip Pro

persistently febrile despite broad-spectrum antibiotic therapy. Antifungal options include a lipid formulation of AmB (strong recommendation; high-quality evidence) , an echinocandin (caspofungin or micafungin) (strong recommendation; high-quality evidence) , or voriconazole (strong recommendation; moderate-quality evidence) . 75. Empiric antifungal therapy is not recommended for patients who are anticipated to have short durations of neutropenia (duration of neutropenia <10 days), unless other findings (...) Practice Guidelines for the Diagnosis and Management of Aspergillosis We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America | Clinical Infectious Diseases | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search

2016 Infectious Diseases Society of America

119. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications Full Text available with Trip Pro

with today’s myriad healthcare-associated factors that predispose to infection. Moreover, changes in pathogen prevalence, in particular a more common staphylococcal origin, have affected outcomes, which have not improved despite medical and surgical advances. Methods and Results— This statement updates the 2005 iteration, both of which were developed by the American Heart Association under the auspices of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular (...) in the management of this uncommon but potentially deadly infection. The clinical variability and complexity in infective endocarditis, however, dictate that these recommendations be used to support and not supplant decisions in individual patient management. Introduction Infective endocarditis (IE) is an uncommon infectious disease with an annual incidence ranging from 3 to 7 per 100 000 person-years in the most contemporary population surveys. Although relatively rare, IE continues to be characterized

2016 Infectious Diseases Society of America

120. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection

eligibility for ART will mean that more people will start ART earlier. Importantly, in this guidance WHO emphasizes the need for differentiated approaches to care for people who are stable on ART, such as reducing the frequency of clinic visits and community ART distribution. Such efficiencies are essential if countries with a high burden of HIV infection are to manage their growing numbers of people receiving ART and reduce the burden on people receiving treatment and health facilities. The second (...) with tuberculosis, hepatitis, and other co-infections. The guidelines are ambitious in their expected impact, and yet simplified in their approach, and firmly rooted in evidence. They take advantage of recent findings from clinical trials confirming that the early use of ART keeps people living with HIV alive and healthier and reduces the risk of transmitting the virus to their sexual and drug-sharing partners. Earlier treatment has the further advantage of simplifying the operational demands on programmes

2016 World Health Organisation HIV Guidelines

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>